CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Heron Therapeutics, Inc. - HRTX CFD

    1.31
    9.17%
    0.05
    Low: 1.16
    High: 1.31
    Market Trading Hours* (UTC) Opens on Monday at 14:30

    Mon - Fri: 14:30 - 21:00

    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.05
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026235 %
    Charges from full value of position ($-4.98)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026235%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.004012 %
    Charges from full value of position ($0.76)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.004012%
    Overnight fee time 22:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Heron Therapeutics Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 1.2
    Open* 1.16
    1-Year Change* -56.72%
    Day's Range* 1.16 - 1.31
    52 wk Range 0.50-3.41
    Average Volume (10 days) 7.15M
    Average Volume (3 months) 57.90M
    Market Cap 196.60M
    P/E Ratio -100.00K
    Shares Outstanding 150.07M
    Revenue 122.84M
    EPS -0.97
    Dividend (Yield %) N/A
    Beta 1.53
    Next Earnings Date Mar 21, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Dec 1, 2023 1.31 0.11 9.17% 1.20 1.31 1.15
    Nov 30, 2023 1.20 -0.07 -5.51% 1.27 1.31 1.19
    Nov 29, 2023 1.27 0.07 5.83% 1.20 1.33 1.20
    Nov 28, 2023 1.19 0.03 2.59% 1.16 1.25 1.10
    Nov 27, 2023 1.29 -0.07 -5.15% 1.36 1.38 1.22
    Nov 24, 2023 1.36 0.07 5.43% 1.29 1.41 1.29
    Nov 22, 2023 1.35 0.05 3.85% 1.30 1.37 1.22
    Nov 21, 2023 1.29 -0.02 -1.53% 1.31 1.40 1.21
    Nov 20, 2023 1.27 0.17 15.45% 1.10 1.36 1.09
    Nov 17, 2023 1.06 0.20 23.26% 0.86 1.08 0.85
    Nov 16, 2023 0.89 0.01 1.14% 0.88 0.92 0.80
    Nov 15, 2023 0.84 0.09 12.00% 0.75 0.89 0.74
    Nov 14, 2023 0.51 -0.02 -3.77% 0.53 0.59 0.51
    Nov 13, 2023 0.52 -0.06 -10.34% 0.58 0.58 0.51
    Nov 10, 2023 0.56 -0.01 -1.75% 0.57 0.57 0.52
    Nov 9, 2023 0.58 -0.13 -18.31% 0.71 0.71 0.57
    Nov 8, 2023 0.70 -0.09 -11.39% 0.79 0.79 0.69
    Nov 7, 2023 0.76 0.02 2.70% 0.74 0.78 0.70
    Nov 6, 2023 0.71 -0.06 -7.79% 0.77 0.77 0.70
    Nov 3, 2023 0.72 0.06 9.09% 0.66 0.74 0.66

    Heron Therapeutics, Inc. Events

    Time (UTC) Country Event
    Thursday, March 21, 2024

    Time (UTC)

    10:59

    Country

    US

    Event

    Q4 2023 Heron Therapeutics Inc Earnings Release
    Q4 2023 Heron Therapeutics Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 107.672 86.346 88.638 145.968 77.474
    Revenue 107.672 86.346 88.638 145.968 77.474
    Cost of Revenue, Total 54.874 46.021 36.189 61.619 27.512
    Gross Profit 52.798 40.325 52.449 84.349 49.962
    Total Operating Expense 282.33 304.174 316.801 356.662 261.411
    Selling/General/Admin. Expenses, Total 119.95 127.332 106.079 127.661 93.867
    Research & Development 107.506 130.821 174.533 167.382 140.032
    Operating Income -174.658 -217.828 -228.163 -210.694 -183.937
    Interest Income (Expense), Net Non-Operating -0.836 -1.977 1.732 5.787 3.293
    Other, Net -6.53 -0.878 -0.847 0.158 1.804
    Net Income Before Taxes -182.024 -220.683 -227.278 -204.749 -178.84
    Net Income After Taxes -182.024 -220.683 -227.278 -204.749 -178.84
    Net Income Before Extra. Items -182.024 -220.683 -227.278 -204.749 -178.84
    Net Income -182.024 -220.683 -227.278 -204.749 -178.84
    Income Available to Common Excl. Extra. Items -182.024 -220.683 -227.278 -204.749 -178.84
    Income Available to Common Incl. Extra. Items -182.024 -220.683 -227.278 -204.749 -178.84
    Diluted Net Income -182.024 -220.683 -227.278 -204.749 -178.84
    Diluted Weighted Average Shares 108.876 98.471 90.774 81.779 73.193
    Diluted EPS Excluding Extraordinary Items -1.67185 -2.2411 -2.50378 -2.50369 -2.4434
    Diluted Normalized EPS -1.67185 -2.2411 -2.50378 -2.50369 -2.4434
    Total Extraordinary Items 0
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 31.762 29.615 30.028 26.557 27.63
    Revenue 31.762 29.615 30.028 26.557 27.63
    Cost of Revenue, Total 20.158 16.854 12.627 14.717 16.175
    Gross Profit 11.604 12.761 17.401 11.84 11.455
    Total Operating Expense 74.165 62.678 50.383 68.439 77.128
    Selling/General/Admin. Expenses, Total 36.435 32.007 26.699 28.177 32.119
    Research & Development 17.572 13.817 11.057 25.545 28.834
    Operating Income -42.403 -33.063 -20.355 -41.882 -49.498
    Other, Net 0.344 0.295 0.486 -0.026 -6.861
    Net Income Before Taxes -42.059 -32.768 -19.869 -41.908 -56.359
    Net Income After Taxes -42.059 -32.768 -19.869 -41.908 -56.359
    Net Income Before Extra. Items -42.059 -32.768 -19.869 -41.908 -56.359
    Net Income -42.059 -32.768 -19.869 -41.908 -56.359
    Income Available to Common Excl. Extra. Items -42.059 -32.768 -19.869 -41.908 -56.359
    Income Available to Common Incl. Extra. Items -42.059 -32.768 -19.869 -41.908 -56.359
    Diluted Net Income -42.059 -32.768 -19.869 -41.908 -56.359
    Diluted Weighted Average Shares 119.719 119.246 119.136 111.735 102.405
    Diluted EPS Excluding Extraordinary Items -0.35131 -0.27479 -0.16678 -0.37507 -0.55035
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.35131 -0.27479 -0.16678 -0.37507 -0.55035
    Interest Income (Expense), Net Non-Operating
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 205.435 254.423 314.196 479.064 447.248
    Cash and Short Term Investments 84.852 157.58 208.491 390.972 332.371
    Cash & Equivalents 15.364 90.541 105.138 71.898 31.836
    Short Term Investments 69.488 67.039 103.353 319.074 300.535
    Total Receivables, Net 52.049 35.499 41.85 39.879 64.652
    Accounts Receivable - Trade, Net 52.049 35.499 41.85 39.879 64.652
    Total Inventory 54.573 48.382 41.905 24.968 39.032
    Prepaid Expenses 13.961 12.962 21.95 23.245 11.193
    Total Assets 250.951 305.706 353.556 512.782 462.179
    Property/Plant/Equipment, Total - Net 29.805 33.563 39.014 33.372 14.677
    Property/Plant/Equipment, Total - Gross 44.098 46.806 49.886 41.397 22.772
    Accumulated Depreciation, Total -14.293 -13.243 -10.872 -8.025 -8.095
    Other Long Term Assets, Total 15.711 17.72 0.346 0.346 0.254
    Total Current Liabilities 82.355 71.058 102.503 96.705 92.019
    Accounts Payable 3.225 3.803 0.525 2.758 16.863
    Accrued Expenses 78.131 66.622 94.577 88.323 70.582
    Notes Payable/Short Term Debt 0 0 7.053 5.624 4.574
    Current Port. of LT Debt/Capital Leases 0
    Other Current Liabilities, Total 0.999 0.633 0.348 0
    Total Liabilities 237.379 228.136 117.064 108.947 92.019
    Total Long Term Debt 149.284 149.082 0 0 0
    Long Term Debt 149.284 149.082
    Total Equity 13.572 77.57 236.492 403.835 370.16
    Preferred Stock - Non Redeemable, Net 0
    Common Stock 1.191 1.02 0.913 0.903 0.782
    Additional Paid-In Capital 1807.85 1689.99 1628.07 1568.32 1330.19
    Retained Earnings (Accumulated Deficit) -1795.45 -1613.43 -1392.75 -1165.47 -960.721
    Other Equity, Total -0.019 -0.006 0.257 0.085 -0.087
    Total Liabilities & Shareholders’ Equity 250.951 305.706 353.556 512.782 462.179
    Total Common Shares Outstanding 119.155 102.005 91.31 90.304 78.174
    Other Liabilities, Total 5.74 7.996 14.561 12.242
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 193.979 165.28 178.159 205.435 223.804
    Cash and Short Term Investments 77.412 33.244 60.022 84.852 121.746
    Cash & Equivalents 34.859 13.462 27.09 15.364 50.438
    Short Term Investments 42.553 19.782 32.932 69.488 71.308
    Total Receivables, Net 63.795 76.693 51.448 52.049 42.188
    Accounts Receivable - Trade, Net 63.795 76.693 51.448 52.049 42.188
    Total Inventory 42.007 44.623 52.059 54.573 52.239
    Prepaid Expenses 10.765 10.72 14.63 13.961 7.631
    Total Assets 229.199 201.224 220.878 250.951 271.952
    Property/Plant/Equipment, Total - Net 26.854 27.361 28.583 29.805 30.823
    Other Long Term Assets, Total 8.366 8.583 14.136 15.711 17.325
    Total Current Liabilities 79.745 86.722 77.9 82.355 93.876
    Accounts Payable 1.86 1.957 4.065 3.225 6.547
    Accrued Expenses 77.885 84.765 73.835 79.13 87.329
    Notes Payable/Short Term Debt 0 0 0 0 0
    Total Liabilities 256.985 240.508 232.307 237.379 249.502
    Total Long Term Debt 149.439 149.387 149.335 149.284 149.234
    Other Liabilities, Total 27.801 4.399 5.072 5.74 6.392
    Total Equity -27.786 -39.284 -11.429 13.572 22.45
    Common Stock 1.411 1.199 1.193 1.191 1.188
    Additional Paid-In Capital 1866.09 1829.81 1815.59 1807.85 1796.91
    Retained Earnings (Accumulated Deficit) -1895.29 -1870.28 -1828.22 -1795.45 -1775.59
    Other Equity, Total -0.001 -0.006 0.009 -0.019 -0.057
    Total Liabilities & Shareholders’ Equity 229.199 201.224 220.878 250.951 271.952
    Total Common Shares Outstanding 141.101 119.956 119.28 119.155 118.774
    Long Term Debt 149.439 149.387 149.335 149.284 149.234
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -182.024 -220.683 -227.278 -204.749 -178.84
    Cash From Operating Activities -146.912 -203.354 -184.82 -124.58 -191.805
    Cash From Operating Activities 2.889 3.021 2.847 2.044 1.513
    Non-Cash Items 42.729 49.387 52.619 48.892 30.946
    Cash Interest Paid 2.25 1.244 0 0 1.183
    Changes in Working Capital -10.506 -35.079 -13.008 29.233 -45.424
    Cash From Investing Activities -3.324 32.729 208.955 -21.783 -278.55
    Capital Expenditures -1.825 -3.022 -6.813 -7.154 -9.171
    Other Investing Cash Flow Items, Total -1.499 35.751 215.768 -14.629 -269.379
    Cash From Financing Activities 75.059 156.028 9.105 186.425 357.608
    Issuance (Retirement) of Stock, Net 75.059 7.065 9.079 186.425 382.608
    Issuance (Retirement) of Debt, Net 0 148.963 -25
    Net Change in Cash -75.177 -14.597 33.24 40.062 -112.747
    Financing Cash Flow Items 0.026
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -32.768 -182.024 -162.155 -120.247 -63.888
    Cash From Operating Activities -24.9 -146.912 -109.378 -72.312 -43.939
    Cash From Operating Activities 0.718 2.889 2.098 1.392 0.721
    Non-Cash Items 7.678 42.729 32.66 21.645 11.212
    Changes in Working Capital -0.528 -10.506 18.019 24.898 8.016
    Cash From Investing Activities 36.834 -3.324 -5.345 30.702 10.946
    Capital Expenditures -0.224 -1.825 -1.411 -1.366 -1.044
    Other Investing Cash Flow Items, Total 37.058 -1.499 -3.934 32.068 11.99
    Cash From Financing Activities -0.208 75.059 74.62 -0.322 -0.637
    Issuance (Retirement) of Stock, Net -0.208 75.059 74.62 -0.322 -0.637
    Net Change in Cash 11.726 -75.177 -40.103 -41.932 -33.63
    Issuance (Retirement) of Debt, Net 0 0 0
    Cash Interest Paid 0 2.25 1.125 1.125
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    Rubric Capital Management LP Hedge Fund 18.9781 26713503 14963503 2023-07-25 MED
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 5.7834 8140722 -273644 2023-06-30 LOW
    Baker Bros. Advisors LP Hedge Fund 5.777 8131678 0 2023-06-30 LOW
    Franklin Advisers, Inc. Investment Advisor/Hedge Fund 5.2649 7410822 -4373808 2023-06-30 LOW
    BlackRock Institutional Trust Company, N.A. Investment Advisor 4.9654 6989211 -112839 2023-06-30 LOW
    JP Morgan Asset Management Investment Advisor 4.1989 5910312 -220901 2023-06-30 LOW
    Great Point Partners, LLC Hedge Fund 3.3656 4737368 -1080000 2023-06-30 HIGH
    Velan Capital Investment Management LP Investment Advisor/Hedge Fund 3.1969 4500000 0 2023-06-30 HIGH
    Palisade Capital Management, LLC Investment Advisor/Hedge Fund 2.9438 4143649 173363 2023-06-30 LOW
    Clearline Capital LP Hedge Fund 1.894 2665984 576692 2023-06-30 HIGH
    State Street Global Advisors (US) Investment Advisor/Hedge Fund 1.6562 2331238 -224755 2023-06-30 LOW
    JW Asset Management, LLC Hedge Fund 1.5682 2207418 2207418 2023-06-30 LOW
    Deep Track Capital LP Hedge Fund 1.4825 2086704 -1148018 2023-06-30 MED
    Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.4595 2054426 79472 2023-06-30 LOW
    Tang Capital Management, LLC Hedge Fund 1.3148 1850760 1300000 2023-06-30 MED
    Tejara Capital Ltd. Investment Advisor 1.1652 1640133 -27386 2023-06-30 HIGH
    Orchard Capital Management LLC Investment Advisor 0.9883 1391080 0 2023-06-30 MED
    Jefferies LLC Research Firm 0.9171 1290924 1290924 2023-06-30 HIGH
    Coho Partners, Ltd. Investment Advisor 0.8888 1251123 0 2023-04-30 LOW
    New York State Common Retirement Fund Pension Fund 0.7892 1110876 39752 2023-06-30 LOW

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Heron Therapeutics, Inc. Company profile

    About Heron Therapeutics Inc

    Heron Therapeutics, Inc. is a commercial-stage biotechnology company. The Company commercializes a portfolio of products to care for acute care and oncology patients. Its oncology care product portfolio includes SUSTOL and CINVANTI. SUSTOL is used for the prevention of acute and delayed nausea and vomiting associated with both moderately emetogenic chemotherapy (MEC), and anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. CINVANTI is an intravenous (IV) formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist. Its acute care product portfolio includes ZYNRELEF (HTX-011), HTX-019, and HTX-034. HTX-011 is a dual-acting local anaesthetic that delivers a fixed-dose combination of the local anaesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. HTX-019 is an investigational agent for the prevention of postoperative nausea and vomiting. HTX-034 is a product candidate for postoperative pain management.

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, Heron Therapeutics Inc revenues decreased 3% to $86.3M. Net loss decreased 3% to $220.7M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects "Research and development - Balancing va decrease of 39% to $66.4M (expense), Stock-based Compensation in SGA decrease of 24% to $11.8M (expense).

    Equity composition

    Common Stock $.01 Par, 02/10, 50M auth., 40,143,227 issd. Insiders own 6.70%. IPO: 8/87, 2M shares @ $7.00 by Allen & Co. 2/92, private placement of 1,150,000 units (1 Share + 1 Warrant). 5/01, Name changed from Advanced Polymer Systems, Inc. FY'01 fncls. are restated. 05/07, 1-for-4 reverse stock split. 01/14, 1-for-20 Reverse stock split.

    Industry: Biotechnology & Medical Research (NEC)

    4242 Campus Point Court, Suite 200
    SAN DIEGO
    CALIFORNIA 92121
    US

    Income Statement

    • Annual
    • Quarterly

    News

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    12:39, 30 November 2023

    Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

    EZ PI expected to drop further but speed of decline

    08:16, 29 November 2023

    A weaker Dollar drives gold higher

    Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

    13:49, 28 November 2023

    Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

    US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

    13:20, 28 November 2023

    RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

    The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

    13:04, 28 November 2023

    Crude prices slide on OPEC+ uncertainty

    Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

    12:55, 28 November 2023
    GBP

    UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?

    UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.

    10:48, 21 November 2023

    People also watch

    Gold

    2,072.25 Price
    +1.760% 1D Chg, %
    Long position overnight fee -0.0193%
    Short position overnight fee 0.0111%
    Overnight fee time 22:00 (UTC)
    Spread 0.30

    Oil - Crude

    74.50 Price
    -1.560% 1D Chg, %
    Long position overnight fee -0.0136%
    Short position overnight fee -0.0083%
    Overnight fee time 22:00 (UTC)
    Spread 0.040

    US100

    16,001.20 Price
    +0.470% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0040%
    Overnight fee time 22:00 (UTC)
    Spread 7.0

    XRP/USD

    0.63 Price
    +0.540% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 22:00 (UTC)
    Spread 0.01168

    Still looking for a broker you can trust?

    Join the 570.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading